Given camera pill
This article was originally published in The Gray Sheet
Executive Summary
Given Imaging's swallowable capsule for visualizing the inside of the small intestine to detect polyps, cancer or causes of bleeding gains FDA market go-ahead Aug. 1 via agency's 510(k) de novo process. The diagnostic imaging system is intended for use in conjunction with other endoscopic or radiological examinations. The capsule incorporates a small camera, lights, image transmitter and eight-hour battery (1"The Gray Sheet" July 30, 2001, p. 14)
You may also be interested in...
Given M2A Camera Pill Suspected Blood Indicator Gains 510(k) Clearance
Given Imaging will upgrade the RAPID software on its M2A camera pill computer workstation within the next 60 days for all U.S. customers with systems under warranty or service contract
Given M2A Camera Pill Suspected Blood Indicator Gains 510(k) Clearance
Given Imaging will upgrade the RAPID software on its M2A camera pill computer workstation within the next 60 days for all U.S. customers with systems under warranty or service contract
Given Plans Software Upgrade On Camera Pill Workstation In Early 2003
Given Imaging is looking to upgrade the software on the entire installed base of its Given M2A camera pill computer workstations in the U.S. in the beginning of 2003